Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model by Magdalena Milczarek et al.
Milczarek et al. BMC Cancer 2013, 13:294
http://www.biomedcentral.com/1471-2407/13/294RESEARCH ARTICLE Open AccessVitamin D analogs enhance the anticancer
activity of 5-fluorouracil in an in vivo mouse colon
cancer model
Magdalena Milczarek1, Mateusz Psurski1,2, Andrzej Kutner3 and Joanna Wietrzyk1*Abstract
Background: Active vitamin D analogs that are less toxic than calcitriol can be useful in the combined treatment
of patients suffering from colon cancer. In the present study we demonstrate, for the first time in an in vivo model
system, the biological effect of combined therapy using 5-fluorouracil (5-FU) along with vitamin D analog PRI-2191
(tacalcitol, 1,24-dihydroxyvitamin D3) or PRI-2205 (5,6-trans-isomer of calcipotriol) on colon cancer.
Methods: We investigated the influence of vitamin D analogs on the anticancer activity of 5-FU or capecitabine in
the treatment of mice bearing MC38 mouse colon tumors implanted subcutaneously or orthotopically. The cell
cycle distribution, E-cadherin expression and caspase 3/7 activity in vitro were also evaluated.
Results: We observed that both PRI-2191 and PRI-2205 significantly enhanced the antitumor activity of 5-FU; but
these results depend on the treatment regimen. Applying the optimal schedule of combined therapy we observed
a significant decrease in tumor growth, metastasis and also a prolongation of the survival time of mice, in
comparison with the administrations of 5-FU given alone. Both combinations indicated a synergistic effect and did
not cause toxicity. Moreover, analogs applied after completed course of administration of 5-FU, prolonged the
antitumor effect of the drug. Furthermore, when the prodrug of 5-FU, capecitabine, was used, potentiation of its
activity was also observed.
Conclusions: Our data suggest that vitamin D analogs (especially PRI-2191) might be potentially applied to clinical
use in order to enhance the anticancer effect of 5-FU and also prolong its activity against colon cancer. The activity
of PRI-2191 is realized through stopping the cells in the G0/G1 cell cycle phase and increasing the expression of
E-cadherin.
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According to the World Health Organization’s Inter-
national Agency for Research on Cancer, colorectal can-
cer is the third most frequent malignancy and the fourth
leading cause of deaths from cancer worldwide [1]. Des-
pite significant progress in the treatment of patients suf-
fering from colorectal cancer in the last decade, there is
a constant need for new therapies. One of the directions
is the development of novel combined treatment* Correspondence: wietrzyk@iitd.pan.wroc.pl
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reproduction in any medium, provided the orstrategies. The benefit of such an approach is the possi-
bility of enhancing the therapeutic effect of a drug,
which is the basis of a standard therapy. Promising can-
didates for this strategy are vitamin D analogs.
Epidemiological and clinical data and also research on
animals suggest a protective role for the active form of
vitamin D (calcitriol, 1,25-dihydroxyvitamin D3) in the
development of colon cancer [2-4]. Data from the
in vivo studies have shown that a diet supplemented
with vitamin D significantly delayed MC-26 colon cancer
tumor growth compared to a diet deficient in thisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and apoptosis of human colon cancer cells. It exerts
a biological effect mainly through the vitamin D receptor
(VDR) [6]. It has been shown that the expression of
VDR increases from normal colon epithelial cells through
precancerous lesions to well-differentiated tumors and
then decreases in advanced stages of cancer [6,7].
The antitumor activity of calcitriol is observed only
when it is applied in hyper-physiological doses, which
can cause the side effect of hypercalcemia and hypercal-
ciuria [8-10]. For this reason, the synthesis of analogs
has been initiated in order to dissociate the calcemic
effect from the anticancer activity of calcitriol. In our
previous studies, we have examined the biological activ-
ity of a series of side-chain modified analogs of vitamin
D and a series of diastereometric and geometric ones
against various cancer and normal cell lines [11,12]. We
also evaluated the influence of vitamin D analogs on the
activity of a range of anticancer drugs in vitro and
in vivo against the human and murine cancer cells
[13-18]. We observed that vitamin D analogs increased
the antitumor effect of cyclophosphamide and cisplatin
compared to the cytostatic drug applied alone. Based on
our results, we selected two analogs for further research:
PRI-2191 (tacalcitol, 1,24-dihydroxyvitamin D3) and
PRI-2205 (5, 6-trans calcipotriol), which reveal higher
antitumor activity and lower calcemic activity, as well as
lower toxicity than calcitriol [12,19]. These two analogs,
used in combined HT-29 colon cancer treatment with
irinotecan or oxaliplatin showed, in selected schedules of
treatment, improvement in mice survival and tumor
growth delay [20].
5-Fluorouracil (5-FU) is one of the oldest anticancer
drugs and is still used in the treatment of colorectal can-
cer [21,22]. Two recent reports of in vitro studies dem-
onstrate that calcitriol and calcipotriol promote the
sensitivity of human colon carcinoma cells to 5-FU and
enhance the cytotoxicity of the FOLFIRI anticancer regi-
men. These results also indicate that the mechanism of
calcitriol and calcipotriol action is dependent on the cal-
cium sensing receptor (CaSR). Protein expression and the
gene transcriptional activity of survivin and thymidylate
synthase are suppressed by inducing the expression and
activation of CaSR by calcitriol or calcipotriol. This leads
to an increase in the sensitivity of colon carcinoma cells to
5-FU [23,24].
Therefore, the aim of our present studies was to examine
the biological effect (antitumor activity, influence on the life
span of mice, toxicity and antimetastatic activity) of com-
bined therapy with the use of 5-FU along with PRI-2191 or
PRI-2205 against MC38 mouse colon cancer in vivo. In
addition, we examined whether vitamin D analogs would
prolong the antitumor activity of 5-FU (application of ana-
logs was initiated after administration of 5-FU ended).Methods
Compounds
Calcitriol and its analogs: PRI-2191, PRI-2201 and
PRI-2205 are certified synthetic materials obtained from
the Pharmaceutical Research Institute, Warsaw, Poland.
Samples of the compounds were stored, under argon, in
amber ampoules at −20°C. Prior to usage, in the case of
in vitro studies, compounds were dissolved in 99.8%
ethanol to the concentration of 10-4 M and subsequently
diluted in culture medium in order to reach the concen-
tration of 100 nM. For animal experiments, compounds
were dissolved in 99.8% ethanol, then diluted in 80%
propylene glycol in order to reach the required concen-
trations and administered subcutaneously (s.c.) or orally
(p.o.) to mice in a volume of 5 μl per 1 g of body weight.
5-Fluorouracil (5-FU) (Ebewe Pharma, Unterach,
Austria) solution in the concentration of 50 mg/ml was
diluted prior to usage in in vitro studies in culture
medium in order to reach the required concentrations
and for in vivo experiments in saline in order to reach
the required concentrations and administered either
intravenously (i.v.) or intraperitoneally (i.p.) to mice at
a volume of 10 μl per 1 g of body weight.
Capecitabine (CPC) (Pharmaceutical Research Institute,
Warsaw, Poland) was dissolved in 40% ethanol, then
diluted in water for injection in order to reach the require
concentration and administered orally (p.o.) to mice at
a volume of 10 μl per 1 g of body weight.
Cell lines
The mouse colon adenocarcinoma cell line MC38, cul-
tured in vivo, was obtained from the Tumor Bank of the
TNO Radiobiology Institute, Rijswijk, Holland. This cell
line was adapted to growth in vitro as MC38/0 [25]. The
MC38/EGFP mouse colon cancer cells, transduced with
green fluorescent protein gene and cultured in vitro,
were obtained from the Institute of Immunology and
Experimental Therapy, Wroclaw, Poland [25]. Human
colon adenocarcinoma cell lines HT-29 and LoVo were
received from the Deutsches Krebsforschungszentrum,
Heidelberg, Germany. All cell lines were stored in
liquid nitrogen at the Cell Culture Collection of the
Institute of Immunology and Experimental Therapy,
Wroclaw, Poland.
The cell lines were cultured in vitro as follows: MC38/0
and MC38/EGFP in RPMI 1640 medium (IIET, Wroclaw,
Poland), HT-29 and LoVo in RPMI 1640 + Opti-MEM
I (1:1) (from IIET, Wroclaw, Poland and Gibco,
Scotland, UK, respectively) all culture media were
supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate (both from Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), 5% fetal bovine serum (PAA
Laboratories GmbH, Pasching, Austria (MC38/0 and
MC38/EGFP) or Thermo Fisher Scientific Inc., UK
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streptomycin (both from Polfa Tarchomin S.A.
Warsaw, Poland). The cells were cultured at 37°C in
a humid atmosphere saturated with 5% CO2.
Mice
C57BL/6 female, 12-16-week-old mice, weighing 20–25 g
were obtained from the Maria Sklodowska-Curie Institute –
Oncology Center (Warsaw, Poland) and maintained
under specific pathogen-free (SPF) conditions. All experi-
ments were performed according to EU Directive 2010/
63/EU for animal experiments and were approved by the
1st Local Committee for Experiments with the Use of La-
boratory Animals, Wroclaw, Poland.
Details of the treatment schedules
The MC38 colon cancer cells were passaged in vivo.
Subcutaneous transplantation: mice were subcutane-
ously (s.c.) inoculated in the right flank region with
a 33% suspension of homogenized MC38 tumor tissue
coming from s.c. tumors from another mouse, 0.25 ml
per mouse. Orthotropic transplantation: the anesthetized
mouse was placed on a wooden board in the right lateral
position and the incision was made through the left
upper abdominal pararectal line and peritoneum. The
cecal wall was carefully exposed, placed and fixed be-
tween layers of sterile gauze. 1 – 2 mm piece of speci-
men, derived from primary tumor grown s.c. in another
mouse, was fixed to the serosal part of cecal wall with
5–0 surgical sutures. After implantation, the peritoneum
and abdominal wall was sutured with 4–0 surgical sutures
(Dexon-“S”, Polfa, Poznań, Poland). Tumor cell transplanta-
tions were performed under general anesthesia with
the mixture of ketamine hydrochloride (100 mg/kg,
Ketamina 10%, Biowet, Puławy, Poland) and xylazine hydro-
chloride (20 mg/kg, XylaRiem, Riemser Arzneimittel AG,
Germany).
The MC38/EGFP colon cancer cells derived from
in vitro culture were inoculated s.c. in the right flank
region with 1 × 106 cells suspended in 0.2 ml saline per
mouse. After tumor inoculation, mice were randomly di-
vided into different groups (day 0).
The evaluation, both the most effective dose and treatment
schedule of vitamin D analogs in combination with 5-FU
Vitamin D analog was administered s.c. three times a
week. In these experiments, different doses of vitamin D
analogs and varied doses and treatment schedules of 5-FU
were studied (Table 1 – 5-FU and PRI-2191, Table 2 –
5-FU and PRI-2205). In each experiment, mice bearing s.c.
MC38 colon cancer cells were randomly divided into
different groups (day 0). Then, the mice were injected
with 5-FU and/or vitamin D analogs.Vitamin D analog was administered s.c. five times a
week. Mice bearing s.c. MC38 colon cancer cells were
i.v. injected with 5-FU at a dose of 100 mg/kg/day on
days: 2, 17 and/or vitamin D analogs: PRI-2191 at a dose
of 0.2 μg/kg/day or PRI-2205 at a dose of 20 μg/kg/day.
Both analogs were administrated s.c., five times a week on
days: 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25.
Vitamin D analog was administered p.o. three times a
week. Mice bearing s.c. MC38 colon cancer cells were i.v.
injected with 5-FU at a dose of 100 mg/kg/day on days:
9, 16, 23 and/or vitamin D analogs: PRI-2191 at a dose of
1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both
analogs were administrated p.o. by gavage, directly into
the lower esophagus using a feeding needle, three times
a week on days: 12, 14, 16, 19, 21, 23, 26, 28.
The effect of combined therapy with 5-FU and PRI-2191
or PRI-2205 on MC38 colon tumor growth implanted
orthotopically
Mice bearing MC38 tumors implanted i.i. were i.v.
injected with 5-FU at a dose of 100 mg/kg/day on days:
8, 15 and/or vitamin D analogs: PRI-2191 at a dose of
1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both
analogs were administrated s.c., three times a week on
days: 10, 13, 15, 17, 20. Mice were sacrificed on day 22
after i.i. transplantation, tumors were weighed and blood
was collected.
The prolongation of 5-FU antitumor activity by PRI-2191
or PRI-2205
Mice bearing s.c. MC38 colon cancer cells were i.v.
injected with 5-FU at a dose of 100 mg/kg/day on days:
20, 24, 28, 34. When 5-FU reduced tumor volume by
about 90% in comparison to the control group, the ad-
ministration of analogs was initiated (after administra-
tion of the cytostatic drug ended). Both analogs were
administrated s.c., three times a week on days: 35, 38,
40, 42, 45, 47, 49, 52, 54, 56, PRI-2191 at a dose
of 1 μg/kg/day and PRI-2205 at a dose of 10 μg/kg/day.
The antimetastatic effect of combined therapy with 5-FU
and PRI-2191 or PRI-2205
Mice bearing s.c. MC38/EGFP colon cancer cells were i.p.
treated with 5-FU at a dose of 75 mg/kg/day on days:
19, 24, 29 and/or vitamin D analog PRI-2191 at a dose of
1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both
analogs were administrated s.c., three times a week on
days: 19, 21, 24, 26, 28, 31, 33, 35, 38, 40, 42, 45, 47, 49,
52, 54, 56. On the 59th day of the experiment the lymph
nodes were isolated and then observed under
a NightOWL II LB 983 device at Wroclaw University of
Environmental and Life Sciences, Poland, in order to
visualize and calculate the metastasis of s.c. tumor cells to
regional lymph nodes, liver, spleen and lung. Only the
Table 1 The effect of vitamin D analog PRI-2191 (in varied doses) alone or in combination with 5-FU on tumor growth, life span and body weight of mice
bearing subcutaneous colon cancer MC38
No. 5-FU PRI-2191
TGI [%] ILS [%] Maximal decrease
in body weight [%]
5-FU PRI-2191 5-FU+ %H TGI Effect 5-FU PRI-2191 5-FU+ %H ILS Effect 5-FU PRI-2191 5-FU+
PRI-2191 PRI-2191 PRI-2191
1 75 mg/kg; 2 μg/kg 48 6 70* 51 Synergism 21 53 41 62 Antagonism 7 18 19
2 150 mg/kg; 2 μg/kg 87 44 96* 92 Synergism nt. nt. nt. nt. nt. 9 11 21
3 100 mg/kg; 1 μg/kg 38 6 51 42 Synergism 26 −6 118*a 22 Synergism 4 6 12
4 100 mg/kg; 0.5 μg/kg 38 1 36 39 Antagonism 26 −6 43 22 Synergism 4 3 9
5 100 mg/kg; 0.25 μg/kg 38 −35 36 16 Antagonism 26 3 65 29 Synergism 4 9 9
Vitamin D analog was administered subcutaneously, three times a week.
No. – number of experiment; TGI – tumor growth inhibition; %H TGI: hypothetical tumor growth inhibition; ILS: increase in life span; %H ILS: hypothetical increase in life span; nt.: not tested; No. 1 – TGI calculated on
the 27th day of the experiment, No. 2, 3, 4, 5 – TGI on the 32nd day of the experiment.
No. 1: 5-FU was injected i.p. on the first day; PRI-2191 was injected on days: 1, 3, 6, 8, 10, 13, 15, 17, 20, 22; Number of mice: control - 10; in the each treatment group - 8.
No. 2: 5-FU was injected i.p. on days: 9, 16, 23; PRI-2191 was injected on days: 11, 14, 16, 18, 21, 23; Number of mice in each group - 8.
No. 3, 4 and 5: 5-FU was injected i.v. on days: 8, 15, 30, 38; PRI-2191 was injected on days: 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44; Number of mice: No. 3, 4 and 5: control – 7; 5-FU – 7, PRI-2191 – 5;


















Table 2 The effect of vitamin D analog PRI-2205 (in varied doses) alone or in combination with 5-FU on tumor growth, life span and body weight of mice
bearing subcutaneous colon cancer MC38
No. 5-FU PRI-2205
TGI [%] ILS [%] Maximal decrease
in body weight [%]
5-FU PRI-2205 5-FU+ %H TGI Effect 5-FU PRI-2205 5-FU+ %H ILS Effect 5-FU PRI-2205 5-FU+
PRI-2205 PRI-2205 PRI-2205
1 75 mg/kg; 10 μg/kg 48 7 76* 44 Synergism 21 2 77*a 23 Synergism 7 10 8
2 50 mg/kg; 10 μg/kg 30 −16 70 19 Synergism 12 0 38* 12 Synergism 0 0 0
3 150 mg/kg; 10 μg/kg 87 25 96* 90 Synergism nt. nt. nt. nt. nt. 9 1 19
4 100 mg/kg; 5 μg/kg 31 −12 26 23 Antagonism 26 −6 12 22 Antagonism 4 1 6
5 100 mg/kg; 2.5 μg/kg 31 −41 19 2 Antagonism 26 −15 32 16 Synergism 4 7 4
Vitamin D analog was administered subcutaneously, three times a week.
No. – number of experiment; TGI – tumor growth inhibition; %H TGI: hypothetical tumor growth inhibition; ILS: increase in life span; %H ILS: hypothetical increase in life span; nt.: not tested; No. 1 – TGI calculated on
the 27th day of the experiment, No. 2, 4, 5 - TGI on the 30th day of the experiment; No. 3 – TGI on the 32nd day of the experiment.
No. 1: 5-FU was injected i.p. on the first day; PRI-2205 was injected on days: 1, 3, 6, 8, 10, 13, 15, 17, 20, 22; Number of mice: control - 10; in the each treatment group - 8.
No. 2: 5-FU was injected i.p. on days: 2, 7, 11, 16; PRI-2205 was injected on days: 2, 4, 7, 9, 11, 14, 16, 18, 21; Number of mice: control – 9, 5-FU – 8, 5-FU + PRI-2205 – 8, PRI-2205 – 7.
No. 3: 5-FU was injected i.p. on days: 9, 16, 23; PRI-2205 was injected on days: 11, 14, 16, 18, 21, 23, 25, 28; Number of mice in each group - 8.
No. 4 and 5: 5-FU was injected i.v. on days: 8, 15, 30, 38; PRI-2205 on days: 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44; Number of mice: No. 4 and 5: control – 7, 5-FU – 7, PRI-2205 – 5, 5-FU + PRI-2205 – 6;
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lymph nodes were observed.
The effect of combined therapy with capecitabine and
PRI-2191 or PRI-2205 on MC38 colon tumor growth
implanted subcutaneously
Mice bearing MC38 tumors implanted s.c. were p.o.
(by gavage, directly into the lower esophagus using a
feeding needle) administered with capecitabine at a dose
of 450 mg/kg/day on days: 3, 4, 5, 6, 7, 10, 11, 12, 13, 14
and/or vitamin D analogs: PRI-2191 at a dose of 1 μg/kg/day
or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were
administrated s.c., three times a week on days: 3, 5, 7, 10,
12, 14, 17, 19, 21, 24, 26, 28, 31, 33, 35, 38, 40, 42, 45,
47, 49, 52, 54.
Evaluation of the therapeutic effect
Tumor volume was calculated using the formula (a2 × b)/2,
where a = shorter tumor diameter in mm and b = longer
tumor diameter in mm. Inhibition of tumor growth was
calculated from the following formula: tumor growth inhib-
ition (TGI) [%] = 100 – [(WT/WC) × 100], where WT is the
median tumor weight of treated mice and WC – that of
untreated control mice. Mice obviously sick were sacrificed
and the increase in life span (ILS) of treated mice over
the control was evaluated. ILS was calculated from the
following formula: 100 – [(MSTT/MSTC) × 100], where
MSTT is the median survival time of treated animals, and
MSTC is the median survival time of untreated control
mice.
Evaluation of combination effects
The TGI and ILS values were then compared with hypothe-
tical tumor growth inhibition: %H TGI or %H ILS = 100 -
[(100 - E for cytostatic) × (100 - E for vitamin D analog) /100]
[26], where E was TGI or ILS.
As the result of the comparison of TGI to TGI hypothe-
tical value (%H TGI) or ILS to ILS hypothetical value
(%H ILS) the type of interaction between two compounds
in combined treatment was designated, which can be:
 synergy – when the experimental value of TGI/ILS
is greater than hypothetical TGI/ILS;
 additive effect – when those two values are
comparable;
 subadditive effect – if the experimental TGI/ILS
value is smaller than the hypothetical, but larger
than TGI/ILS for cytostatic given alone;
 antagonism – if the experimental TGI/ILS is smaller
than the experimental TGI/ILS for cytostatic.
Tumor growth delay
Tumor growth delay (TGD) is a parameter describing
the time needed for tumors to reach the volume of1 cm3. It can be also expressed as the direct difference in
days: ΔTGDcontrol = TGD treated group–TGDcontrol, where
TGDtreated group are the days needed to reach the volume of
1 cm3 for tumors in the treated group and TGDcontrol the
days needed for tumors to reach the volume of 1 cm3 in
control group. In the case of combined treatment:
ΔTGDcytostatic = TGDtreated group–TGDcytostatic, where
TGDcytostatic are the days needed for tumors to reach the
volume of 1 cm3 in the treated group with cytostatic drugs.
Body weight changes
The average body weight change (BWC) in all groups was
calculated using the formula: BWC= (ABWn/ABW1) ×
100 – 100%, where ABWn is the average body weight on
the nth-day of experiment (during treatment) and ABW1
is the average body weight on the first day of treatment.
Blood leukocytes and platelets
The level of blood leukocytes and platelets was measured
in each individual blood sample (Sysmex K4500SL, serial
number F2872, Japan).
Serum calcium level
Female BALB/c mice were treated i.p. with 5-FU at
a dose of 50 and 75 mg/kg on days 1 and 8, respectively
and/or with vitamin D analogs: PRI-2191 at a dose of
2 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both
analogs were administrated s.c., three times a week on
days: 1, 3, 6, 8, 10, 13. Mice were sacrificed 16 days after
the first injection of the compounds and blood sera were
collected. The calcium level was measured in each indi-
vidual serum sample with the photometric Arsezano 3
method (Olympus AU400; Olympus America Inc., Melville,
NY, USA).
An anti-proliferative assay in vitro
24 hours before the addition of the tested compounds,
cells were plated in 96-well plates (Sarstedt, Newton,
NC, USA) at a density of 2 × 104 cells per well. The cells
were exposed for 120 h to 100 nM of calcitriol,
PRI-2191, PRI-2205 or PRI-2201 and simultaneously to 5-
FU: 0.1 μg/ml (HT-29 and LoVo) or 0.01 μg/ml (MC38/
0); and the SRB assay for evaluating the cytostatic effect
was performed as described previously [12]. The results
were calculated as the proliferation inhibition of the can-
cer cell population. Each compound was tested four-fold
either alone or in combined treatment in a single experi-
ment, which was repeated 3–5 times.
The percentage of proliferation inhibition was calculated
according to the formula: % of proliferation inhibition =
[(At-Am)/(Ac-Am)*100]-100; where: At – absorbance
of treated cells; Am – absorbance of culture medium;
Ac – absorbance of control cells. The value of the percent-
age of proliferation inhibition was then compared with the
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%H= 100-[(100-E for cytostatic) x (100-E for calcitriol
analog) /100], where E was the mean value of the percent-
age of proliferation inhibition in order to determine the
interaction between two compounds in combined treat-
ment [26]. The type of interaction was described above.
Cell cycle analysis
Cultured HT-29 cells were seeded at a density of
7.5 × 103 cells/ml of culture medium on 6-well plates
(Corning, NY, USA) to a final volume of 4 ml. The cells
were exposed to compounds at set concentrations for
120 h: PRI-2191 and PRI-2205 100 nM; 5-FU 0.1 μg/ml.
Ethanol, used as a solvent for all compounds, diluted corre-
sponding to its highest concentration, produced no toxicity
when applied to the compounds. After 120 h of incubation,
the cells were collected with the use of trypsin/EDTA, pH 8
(IIET, Wroclaw, Poland), washed in phosphate-buffered sa-
line (PBS) supplemented with 2% of fetal bovine serum and
counted in a hemacytometer. Cells (1 × 106 per sample)
were then washed twice in cold phosphate buffered saline
(PBS) and fixed for 24 h in 70% ethanol at −20°C. The cells
were then washed twice in PBS and incubated with RNAse
(8 μg/ml, Fermentas GmbH, St. Leon-Rot, Germany) at
37°C for 1 h. The cells were stained for 30 min with
propidium iodide (0.5 mg/ml; Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) at 4°C and the cellular DNA
content was determined using a BD FACSCalibur instru-
ment (Becton Dickinson, San Jose, CA, USA) and a ModFit
LT 3.0 program (Verity Software House, Topsham, ME,
USA). The experiment was repeated 4 times.
E-cadherin expression
Cultured HT-29 cells were seeded at a density of
1 × 105 cells/ml of culture medium on 6-well plates
(Corning, NY, USA) to a final volume of 4 ml. The cells
were exposed to compounds at set concentrations for
48 h: PRI-2191 and PRI-2205 100 nM; 5-FU 0.1 μg/ml.
After 48 h of incubation, the cells were collected using a
non-enzymatic cell dissociation solution (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany), washed in
phosphate-buffered saline supplemented with 1% of fetal
bovine serum (1% FBS) and counted in a hemacytome-
ter. The cells (2 × 105 per sample) were washed once
with 1% FBS and then suspended in 0.1 ml of 5% bo-
vine serum albumin solution in PBS (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) and incubated
for 20 min at room temperature. After incubation, the
cells were washed with 1% FBS and then were stained
with anti-E-cadherin conjugated with phycoerythrin
(PE) or anti-IgG1-PE (both from Abcam, Cambridge,
UK) for 30 min in the dark at room temperature. After
incubation, the cells were washed with 1% FBS and
then suspended in 0.3 ml in the same solution. Dataanalysis was performed by flow cytometry using
a BD LSRFortessa instrument (Becton Dickinson, San
Jose, CA, USA). Next, data were analysed in a BD
FACSDiva 6.2 program. The experiment was repeated 3
times.
Active caspase-3/7 and cell death (subG1) analysis
Cultured MC38/0 cells were seeded at a density of
1 × 105 cells/ml of culture medium on 24-well plates for
caspase-3/7 activity assay or 6-well plates for subG1
stage analysis (both from Corning, NY, USA) to a final
volume of 2 ml or 4 ml, respectively. The cells were
exposed to compounds at set concentrations for 48 h:
PRI-2191 and PRI-2205 100 nM; 5-FU 50 and 200 μg/
ml. Ethanol, used as a solvent for all compounds and
diluted corresponding to its highest concentration, pro-
duced no toxicity when applied to the compounds.
Enzymatic caspase-3/7 activity assay
The experiment was based on a previously described
method [27] adapted to cell-based assay. After treat-
ment, MC-38/0 cell were lysed using ice-cold lysis buffer
(50 mM HEPES, 10% (w/v) sucrose, 150 mM NaCl,
2 mM EDTA, 1% (v/v) Triton X-100, pH 7.3) (IIET,
Wroclaw, Poland). After 10 min., 40 μl of each sample
was transferred to a white, 96-well plate (Corning, NY,
USA) containing 160 μl of reaction buffer (20 mM
HEPES, 10% (w/v) sucrose, 100 mM NaCl, 1 mM EDTA,
10 mM DTT, 0.02% (v/v) Trition X-100, pH 7.3) (IIET,
Wroclaw, Poland) with 9 μM Ac-DEVD-ACC
(λex = 360 nm, λem = 460 nm) as a fluorogenic substrate.
Fluorescence increase correlated with caspase-3/7 level
was continuously recorded at 37°C for 90 min using a
Biotek Synergy H4 (Biokom, Warsaw, Poland). Results
were normalized to the protein content determined
using the Lowry method (BioRad, Warsaw, Poland) and
are reported as relative caspase-3/7 activity in compari-
son to the untreated control.
Death cell analysis with propidium iodide staining
(subG1 stage)
After 48 h of incubation the cells were prepared in the
same manner as cells for the assay of cell cycle distribu-
tion described above. Next, data analysis was performed
by flow cytometry using a BD LSRFortessa instrument
(Becton Dickinson, San Jose, CA, USA). Next, data were
analysed in a BD FACSDiva 6.2 program. The experi-
ment was repeated 4 times.
Statistical evaluation
Statistical analysis of in vivo results was performed by
employing STATISTICA version 7.1 (StatSoft, Inc.,
USA). For tumor growth inhibition analysis and for
antimetastatic effect analysis the Kruskal-Wallis ANOVA
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For survival analysis, the Peto & Peto modification of
the Gehan-Wilcoxon test was used. The results of in vitro
studies were analysed by employing STATISTICA version
10 (StatSoft, Inc., USA) using the Mann–Whitney U test
for cell cycle, E-cadherin expression and death cell
(subG1) analysis as well as the Tukey HSD test for
caspase-3/7 activity assay. P values less than 0.05 were
considered significant.Figure 1 The influence of PRI-2191 on the antitumor activity of
5-FU in MC38 colon cancer. PRI-2191 was administered at a dose
of 1 μg/kg/day, s.c., three times a week, from days 9 to 44, 5-FU
at a dose of 100 mg/kg/day, i.v., from days 8 to 38. Black arrows
indicate the days of 5-FU administration, gray arrows – days of PRI-
2191 administration. A) Kinetics of tumor growth (mean of tumor
volume). P < 0.05: 5-FU combined with PRI-2191 in comparison to
the control from days 18 to 25 (Kruskal-Wallis ANOVA Multiple
Comparisons P values (2-tailed) test). B) Tumor growth inhibition
(TGI) and hypothetical TGI values were calculated from days 8 to 32
of the experiment (median of tumor volume). C) Survival analysis of
treated and untreated mice. Number of mice: control – 7; 5-FU – 7,
PRI-2191 – 5; 5-FU + PRI-2191 – 6.Results
The evaluation of both the most effective dose and
treatment schedule of vitamin D analogs in combination
with 5-FU
The analogs were injected to mice subcutaneously (s.c.)
or orally (p.o.) three or five times a week. We also tested
varied doses of 5-FU, which were administrated once or
repeatedly, intraperitoneally (i.p.) or intravenously (i.v.)
to establish the best scheme of the combined treatment
of mice with MC38 colon cancer.
Analog PRI-2191 or PRI-2205 administered s.c., three
times a week. The analog PRI-2191 was used in the fol-
lowing doses: 2, 1, 0.5 and 0.25 μg/kg/day. Combined
treatment with 5-FU and PRI-2191 (2 μg/kg/day) signifi-
cantly retarded the tumor growth when compared to the
untreated mice. However, the analysis of ILS indicated
an antagonism between both agents. A significant de-
crease was observed in the body weight of mice which
received PRI-2191 alone or in combination with 5-FU
(Table 1, No. 1, 2).
The application of lower doses of PRI-2191 (0.5 or
0.25 μg/kg/day) did not increase the tumor growth in-
hibition caused by 5-FU (in 38% in relation to untreated
mice) (No. 4, 5). On the other hand, treatment with
5-FU and PRI-2191 prolonged the survival of mice by
43% (0.5 μg/kg/day) and 65% (0.25 μg/kg/day), while for
5-FU alone by 26%, but not in a statistically significant
manner (Table 1, No. 4, 5).
Our results indicate that the best effective dose for
analog PRI-2191 is 1 μg/kg/day in combined treatment
with 5-FU (Table 1, No. 3, Figure 1). In this case, the
analysis of TGI (Figure 1B) as well as ILS (Table 1, No. 3)
indicated synergy between 5-FU and PRI-2191. A statis-
tically significant prolongation of the survival of mice
treated with both agents (118%) was observed in com-
parison with 5-FU alone (26%), as well as with un-
treated mice (Table 1, No. 3; Figure 1C). The combined
treatment retarded tumor growth from the 8th day to
the end of the experiment as compared to 5-FU treat-
ment alone (in a statistically significant manner from
the 18th to 25th day compared to untreated mice)
(Figure 1A). The maximal decrease in body weight did
not exceed 12%.
Figure 2 The influence of PRI-2205 on the antitumor activity of
5-FU in MC38 colon cancer. PRI-2205 was administered at a dose of
10 μg/kg/day, s.c., three times a week, from day 1 to 22, 5-FU at a dose
of 75 mg/kg/day, i.p., on the first day. Black arrow indicate day of 5-FU
administration, gray arrows – days of PRI-2205 administration.
A) Kinetics of tumor growth (mean of tumor volume). P < 0.05: 5-FU
combined with PRI-2205 in comparison to the control from days 10 to
27 (Kruskal-Wallis ANOVA Multiple Comparisons P values (2-tailed) test).
B) Tumor growth inhibition (TGI) and hypothetical TGI values were
calculated from days 13 to 27 of the experiment (median of tumor
volume). C) Survival analysis of treated and untreated mice. Number of
mice: control - 10; in the each treatment group – 8. Statistical analysis
was performed for tumor growth inhibition.
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did not improve the therapeutic effect of 5-FU (Table 2,
No. 4). In the case of the application of a lower dose
(2.5 μg/kg/day), prolonged survival of mice was observed
when treated with both agents, but not in a significant
manner. Moreover, the interaction between both agents
in the case of TGI analysis indicated antagonism
(Table 2, No. 5). The results indicate that the most ef-
fective dose for PRI-2205 is 10 μg/kg/day. We performed
three experiments, in which the same dose of PRI-2205
(10 μg/kg/day) and also varied doses and treatment
schedules of 5-FU (50, 75 or 150 mg/kg/day) were ap-
plied. A synergistic effect was observed in the case of
TGI as well as ILS, independent of the dose of 5-FU
(Table 2, No. 1, 2, 3; Figure 2A, B, C). However, the
combined treatment with the highest dose of 5-FU
(150 mg/kg/day) caused high toxicity (Table 2, No. 3).
Analog PRI-2191 or PRI-2205 was administered s.c.,
five times a week. Both vitamin analogs slightly slowed
down MC38 tumor growth in mice treated with 5-FU
and caused a subadditive or synergistic effect at the end
of the experiment on the 25th day, respectively (Table 2).
Furthermore, only analog PRI-2205 prolonged the sur-
vival of mice treated with 5-FU. This combined treat-
ment was not toxic (Table 3).
Analog PRI-2191 or PRI-2205 administered p.o., three
times a week. Combined treatment with PRI-2191 de-
creased tumor growth by 81%, while 5-FU alone by 72%
(P > 0.05). The interaction between both agents indicated
synergy. The maximal decrease in body weight did not
exceed 15% (Table 4). However, analog PRI-2205 admin-
istered orally did not improve the therapeutic effect of
5-FU (Table 4).
The effect of combined therapy with 5-FU and PRI-2191
or PRI-2205 on MC38 colon tumor growth - implanted
orthopically
As described above, the most effective treatment sched-
ule and dose of both vitamin D analogs is s.c. injection,
three times a week and at a dose of 1 μg/kg/day for
PRI-2191 and 10 μg/kg/day for PRI-2205. In this experi-
ment, we evaluated the influence of vitamin D analogs
(in the most effective dose and treatment schedule) on
the antitumor activity of 5-FU in the treatment of mice
bearing MC38 colon tumors transplanted orthopically.
On the 22nd day of the experiment, intestinal tumors
were isolated and weighed. In mice treated with 5-FU
alone, the reduction of tumor weight was 79% when
compared to untreated mice (P > 0.05). Combined treat-
ment with 5-FU and PRI-2191 significantly (94%) re-
duced the intestinal tumor growth. The interaction
between these two compounds indicated synergy
(Figure 3A, Table 4). The kinetics of body weight
changes in treated and untreated mice is illustrated inFigure 3B. The combined treatment with 5-FU and
PRI-2191 did not cause toxicity. The maximal decrease in
body weight did not exceed 5% (Figure 3B). The analog




TGI [%] on the 25th day of the experiment ILS [%] Maximal decrease
in body weight [%]
5-FU AN 5-FU + AN %H TGI Effect 5-FU AN 5-FU + AN %H ILS Effect 5-FU AN 5-FU + AN
PRI-2191 100 mg/kg 0.2 μg/kg 69 42 73 82 Subadditive 63 4 67 64 No effect 4 7 4
PRI-2205 100 mg/kg 20 μg/kg 69 −16 72 64 Synergism 63 0 83 62 Synergism 4 5 1
Vitamin D analog was administered subcutaneously, five times a week.
AN Analog of vitamin D, TGI Tumor growth inhibition, %H TGI Hypothetical tumor growth inhibition, ILS Increase in life span, %H ILS Hypothetical increase in life span, Number of mice: control - 9; PRI-2191 – 7,
PRI-2205: 7, 5-FU: 5, 5-FU + PRI-2205: 6, 5-FU + PRI-2191 – 7.
Mice bearing s.c. MC38 colon cancer cells were i.v. injected with 5-FU at a dose of 100 mg/kg/day on days: 2 and 17 and/or vitamin D analogs: PRI-2191 at a dose of 0.2 μg/kg/day or PRI-2205 at a dose of


















Table 4 The effect of vitamin D analog (in the most effective dose, administered orally) alone or in combination with
5-FU on tumor growth and body weight of mice bearing subcutaneously MC38 colon cancer
Analog
(AN) 5-FU AN
TGI [%] on the 21st day of the experiment Maximal decrease
in body weight [%]
5-FU AN 5-FU + AN %H TGI Effect 5-FU AN 5-FU + AN
PRI-2191 100 mg/kg 1 μg/kg 72 12 81 75 Synergism 2 5 15
PRI-2205 100 mg/kg 10 μg/kg 72 6 73 73 No effect 2 5 5
Vitamin D analog was administered orally (p.o.), three times a week.
AN Analog of vitamin D, TGI Tumor growth inhibition; %H TGI, Hypothetical tumor growth inhibition; Number of mice in each group - 8.
Mice bearing s.c. MC38 colon cancer cells were i.v. injected with 5-FU at a dose of 100 mg/kg/day from days 9 to 23 and/or vitamin D analogs: PRI-2191 at a dose
of 1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were administrated p.o., three times a week from days 12 to 28.
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(Figure 3A).
On the other hand, 5-FU applied alone increased the
number of blood leukocytes and platelets in relation to
the control mice. In mice treated with 5-FU and
PRI-2191 or PRI-2205, the tendency for a decrease in
the number of blood leukocytes was noted in compari-
son with 5-FU alone, but there was no change compared
to control. In terms of the number of platelets, no differ-
ence between 5-FU alone and in combined treatment
was observed (Table 5).
The prolongation of 5-FU antitumor activity by PRI-2191
or PRI-2205
The application of analogs was started from the 35th
day of the experiment after the end of 5-FU administra-
tion (i.e. when cytostatic reduced tumor volume by 90%
in relation to control untreated mice). As shown in
Figure 4, after treatment with 5-FU alone ended a rapid
increase in tumor growth was noted. However, in the
case of combined treatment, we observed that the appli-
cation of vitamin D analogs prolonged the antitumor ac-
tivity of 5-FU. Both analogs delayed tumor growth as
well as prolonged the survival of mice in comparisonFigure 3 The effect of PRI-2191 or PRI-2205 alone or in combination
tumor weight. B) Body weight of mice during treatment. Mice bearing MC
100 mg/kg/day on days 8 and 15 and vitamin D analogs: PRI-2191 at a dos
were administrated s.c., three times a week from days 10 to 20. Mice were
weighed and blood was collected. Black arrows indicate the days of 5-FU a
Number of mice: control - 7; PRI-2191 – 4, PRI-2205: 6, 5-FU: 6, 5-FU + PRI-2
control; *P < 0.05 – 5-FU + PRI-2191 compared to PRI-2191.with 5-FU given alone (Figure 4, Table 6). Better results
were observed in the case of PRI-2191 than PRI-2205.
To compare the time needed to reach 1 cm3 tumor of
volume in the treated groups in relation to the control
group, tumor growth delay (TGD) was calculated. As
shown in Table 6, administration of 5-FU alone delayed
tumor growth by 23 days compared to untreated mice,
in the case of combined treatment by 27 days using
PRI-2205 and 32 days using PRI-2191. Moreover, the
105% prolongation of the survival of mice treated with
PRI-2191 after 5-FU was noted, while prolongation
amounted by 76% with 5-FU alone (Table 6). In addition,
no toxicity for 5-FU and combined treatment was ob-
served (data not shown).
The antimetastatic effect of combined therapy with 5-FU
and PRI-2191 or PRI-2205
Next, we investigated the influence of vitamin D analogs
on regional lymph node metastasis formation in the
treatment of mice bearing MC38/EGFP colon cancer
cells. The combined treatment using 5-FU and PRI-2191
significantly decreased colon cancer metastasis to lymph
nodes compared to 5-FU applied alone (Figure 5). The
application of 5-FU and PRI-2191 decreased metastasiswith 5-FU on MC38 tumors transplanted ortotopically. A) Intestinal
38 tumors implanted i.i. were i.v. injected with 5-FU at a dose of
e of 1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs
sacrificed on the 22nd day after i.i. transplantation, tumors were
dministration, gray – days of vitamin D analogs administration.
191 – 7; 5-FU + PRI-2205: 6; **P < 0.01 – 5-FU + PRI-2191 compared to
Table 5 The influence of PRI-2191 or PRI-2205 alone or in combination with 5-FU on intestinal tumor growth,
leukocytes and platelets in the blood samples from mice with MC38 colon cancer
Group
Tumor weight Leukocytes Platelets
N
Mean ± SD [g] TGI [%] %H TGI Effect Mean ± SD [103/μL] Mean ± SD [103/μL]
Control 1.4 ± 1.06 7.7 ± 3.4 684 ± 309 7
PRI-2191 1.26 ± 0.80 4 7.2 ± 1.4 835 ± 170 4
PRI-2205 0.86 ± 0.93 35 8.7 ± 2.3 887 ± 67 6
5-FU 0.28 ± 0.27 79 15.5 ± 5.7 1186 ± 207**c 6
5-FU + PRI-2191 0.08 ±0.15**a,*b 94 80 Synergism 8.6 ± 3.0 1159 ± 254**c 7
5-FU + PRI-2205 0.32 ± 0.25 75 86 Antagonism 7.6 ± 4.1 1046 ± 320 6
TGI, Tumor growth inhibition; %H TGI, Hypothetical tumor growth inhibition; N, Number of mice in group; SD, Standard deviation.
**a P < 0.01 as compared to control; *b P < 0.05 as compared to PRI-2191: Kruskal-Wallis ANOVA (Multiple Comparisons p values (2-tailed)); **c P < 0.01 as compared
to control: Tukey HSD.
Mice bearing MC38 tumors implanted i.i. were i.v. injected with 5-FU at a dose of 100 mg/kg/day on days: 8, 15 and/or vitamin D analogs: PRI-2191 at a dose of
1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were administrated s.c., three times a week from days 10 to 20. Mice were sacrificed on day 22
after i.i. transplantation, tumors were weighed and blood was collected.
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5-FU alone it was up to 2 times (data not shown). More-
over, an 80% inhibition of tumor growth was observed
on the 49th day of experiment for combined treatment
with PRI-2191 and 62% for 5-FU alone. The interaction
between these two agents indicated synergy. No toxicity
for 5-FU either alone or in combined treatment was
observed (data not shown). However, analog PRI-2205
had no effect on the antimetastatic activity of 5-FU
(Figure 5).Figure 4 The anticancer activity of vitamin D analogs injected
after the completion of 5-FU administration in the treatment of
mice bearing MC38 colon cancer. The kinetics of tumor growth
(mean tumor volume). Mice bearing s.c. MC38 colon cancer cells
were i.v. injected with 5-FU at a dose of 100 mg/kg/day from days
20 to 34. When 5-FU reduced tumor volume by about 90% in
comparison to the control group, the administration of analogs was
initiated (after administration of the cytostatic drug ended). Both
analogs were administrated s.c., three times a week from days 35 to
56, PRI-2191 at a dose of 1 μg/kg/day and PRI-2205 at a dose of
10 μg/kg/day. Black arrows indicate the days of 5-FU administration,
gray – days of vitamin D analog administration. Number of mice inThe effect of combined therapy with capecitabine and
PRI-2191 or PRI-2205 on MC38 colon tumor growth -
implanted subcutaneously
Capecitabine used at a dose of 450 mg/kg/day, signifi-
cantly retarded MC38 tumor growth from day 14 to 35
as compared to the control group (P < 0.05). In a com-
bined treatment strategy, PRI-2191 and PRI-2205 im-
proved the effect of capecitabine (Figure 6A). Both
analogs applied in combined treatment with capecitabine
significantly retarded the growth of tumors (P < 0.05 from
days 10 to 35 – PRI-2191, and from days 10 to 33 –
PRI-2205). On day 17 of the experiment a complete re-
gression of tumor growth was observed in mice treated
with capecitabine and this lasted until day 20. Both ana-
logs shortened the time for the regression of capecitabine
treated tumors: tumors disappeared on day 12, and oc-
curred on day 24 of the experiment (Figure 6B). Maximal
body weight decrease reaching 5% was observed in mice
treated with capecitabine alone or combined with
PRI-2191 (data not shown).the control group – 8 and in each treated group – 6. Statistical
analysis: Kruskal-Wallis ANOVA Multiple Comparisons P values
(2-tailed) test. P < 0.05 compared to control group: 5-FU from days
26 to 33, 5-FU + PRI-2191 as well as 5-FU + PRI-2205 from days 28 to
35. On day 35 the control group was sacrificed because of large size
of tumors.Calcemic activity of combined treatment
The results of the serum calcium level evaluation after s.c.
injection of PRI-2191 or PRI-2205 (2 and 10 μg/kg/day),
estimated on 16 day after the first injection, are illustratedin Table 7. Calcium level in serum of mice treated with
PRI-2191 alone or combined with 5-FU was significantly
higher than this in untreated mice. However, administra-
tion of 10 μg/kg/day of PRI-2205 did not affect calcium
level.
Table 6 Tumor growth delay values for each group and
survival analysis of mice
Group
The time needed for tumors to reach
ILS
[%] N





Control 24 — — 8
5-FU 47 23 76** 6
5-FU + PRI-2205 50 27 3 97 6
5-FU + PRI-2191 56 32 9 105** 6
N Number of mice in group, TGD Tumor growth delay,
ΔTGDcontrol = TGD treated group–TGDcontrol,
ΔTGDcytostatic = TGDtreated group–TGDcytostatic, ILS increase in life span,
**P < 0.01
as compared to control.
Mice bearing s.c. MC38 colon cancer cells were i.v. injected with 5-FU
at a dose of 100 mg/kg/day from days 20 to 34. When 5-FU reduced tumor
volume by about 90% in comparison to the control group, the administration
of analogs was initiated (after administration of the cytostatic drug ended).
Both analogs were administrated s.c., three times a week from days 35 to 56,
analog PRI-2191 at a dose of 1 μg/kg/day and PRI-2205 at a dose
of 10 μg/kg/day.
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In these studies we used two reference compounds,
namely calcitriol and calcipotriol (PRI-2201). As shown
in Table 6, most sensitive to the antiproliferative activity
of vitamin D compounds among the cell lines tested is
human colon cancer HT-29. Moreover, the potentiationFigure 5 The metastasis of MC38/EGFP colon cancer cells to
lymph nodes in mice treated with 5-FU and PRI-2191
or PRI-2205. Mice bearing s.c. MC38/EGFP colon cancer cells were i.p.
treated with 5-FU at a dose of 75 mg/kg/day from days 19 to 29 alone
and in combination with vitamin D analog PRI-2191 at a dose of 1 μg/
kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were
administrated s.c., three times a week from days 19 to 56. The mean
fluorescence intensity value of the green fluorescent protein which is
directly proportional to the number of MC38/EGFP cells in lymph
nodes isolated from mice on the 59th day of the experiment was
calculated. The number of mice in each group – 7. Statistical analysis
was performed using the Kruskal-Wallis ANOVA Multiple Comparisons
P values (2-tailed) test. ***P < 0.001 – 5-FU + PRI-2191 compared to
5-FU; **P < 0.01 – 5-FU + PRI-2191 compared to 5-FU + PRI-2205.for 5-FU antiproliferative effect by vitamin D com-
pounds was clearly observed on this cell line (Table 8).
Other cell lines were less sensitive or almost non-
sensitive to proliferation inhibition by vitamin D analogs.
However, when MC38/0 cells were incubated with low
concentrations of 5-FU, proliferation was inhibited by
9% and raised to 41% when PRI-2205 was included
(Table 8). On the basis of these studies, we chose HT-29
and MC38/0 cells for further in vitro studies. All in vitro
studies on the HT-29 cells described below were
conducted in the same concentrations of compounds,
such as were used in antiproliferative activity tests.
The evaluation of the cell cycle is presented in Figure 7.
As shown in the upper panel of Figure 7, calcitriol,
PRI-2201, as well as PRI-2191 tend to increase the per-
centage of cells in the G0/G1 stage, whereas PRI-2205
did not affect the cells in this phase. This was inversely
correlated with the percentage of cells in the G2/M
phase. Namely, the three mentioned compounds de-
creased the cells in G2/M, but PRI-2205 increased them.
Analyzing the cells treated with 5-FU, we observed that
the cells treated with this agent alone are cumulated in
the S phase and decreased in the G0/G1 and G2/M
phases, when compared to control. Parallel incubation
of cells with calcitriol, PRI-2201 and PRI-2191, but not
by PRI-2205, increased the percentage of cells in G0/G1
as compared to 5-FU alone. Moreover, the number of
cells in the S and G2/M phases was decreased by these
three compounds as compared to 5-FU. The action of
PRI-2205 was different; this analog either did not influ-
ence or only slightly decreased the cells in G0/G1 and
G2/M, but increased them in the S phase as compared
to 5-FU alone. The percentage of death cells (subG1) did
not on average exceed 10 percent (data not shown).
Moreover, in this lower panel of Figure 7, representative
histograms are presented for control cells, as well as
those incubated with 5-FU alone or combined with
PRI-2191 and PRI-2205.
In the series of in vitro studies we also analyzed the
expression of E-cadherin on HT-29 cells. A statistically
significant increase in this adhesion molecule was ob-
served on cells incubated with 5-FU used in combin-
ation with calcitriol, PRI-2201 and PRI-2191 (Figure 7,
lower panel).
Using higher concentrations of 5-FU, we also analyzed
the subG1 population and the activity of caspase-3/7 in
MC38/0 cells incubated with or without vitamin D ana-
logs (Figure 8 A and B). A statistically significant in-
crease in the percentage of cells in the subG1 stage was
observed independently of the presence of vitamin D
compounds, when cells were incubated with 50 or
200 μg/ml of 5-FU. However, a tendency to increase the
percentage of cells was observed, when the cells were in-
cubated with PRI-2205 and 5-FU (Figure 8B). Under the
Figure 6 MC38 tumor growth in mice treated with capecitabine (CPC) alone and in combination with vitamin D analogs. A) The kinetics
of tumor growth. B) The number of mice with tumors in treated groups during experiment. CPC was administered p.o. at a dose
of 450 mg/kg/day and/or vitamin D analogs: PRI-2191 at a dose of 1 μg/kg/day and PRI-2205 at a dose of 10 μg/kg/day, both were administrated
s.c., three times a week. Black arrows indicate the days of CPC administration and gray – days of vitamin D analog administration. The number of
mice: control - 8; PRI-2191 – 4, PRI-2205: 3, 5-FU: 6, 5-FU + PRI-2191 – 6; 5-FU + PRI-2205: 6. Statistical analysis: Kruskal-Wallis ANOVA Multiple
Comparisons P values (2-tailed) test. P < 0.05 as compared to the control: CPC from days 14 to 35; PRI-2191 in combined treatment with CPC
from days 10 to 35; PRI-2205 in combined treatment with CPC from days 10 to 33.
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3/7 was evaluated. A statistically significant increase in
enzyme activity was observed in cells treated with 5-FU
at a dose of 200 μg/ml alone or with vitamin D analogs.
The activity of caspase-3/7 was slightly diminished by
both analogs as compared to 5-FU alone (Figure 8A).Table 7 Serum calcium level on day 16 after first administrati
Control 5-FU PRI-219
N 5 5 4
Calcium level [mEq/L] 4.97 ± 0.08 5.02 ± 0.09 5.61 ± 0
*Kruskal-Wallis test for multiple comparisons; P < 0.05 as compared to control.
N Number of mice.Discussion
In the present study we demonstrate, for the first time
in an in vivo model, the biological effect of combined
therapy against MC38 mouse colon cancer using 5-FU
along with vitamin D analogs (PRI-2191 - tacalcitol and
PRI-2205 – 5,6-trans-isomer of calcipotriol).on of PRI-2191 or PRI-2205 and 5-FU
1 PRI-2205 PRI-2191 + 5-FU PRI-2205 + 5-FU
5 6 4
.2* 5.04 ± 0.16 5.57 ± 0.16* 5.15 ± 0.06
Table 8 The antiproliferative effect of vitamin D analogs with 5-FU on human and mouse colon cancer cells
Vitamin D
compounds
Colon cancer cell line [%]
HT-29 LoVo MC38/0
+ 5-FU %H + 5-FU %H + 5-FU %H
- 8 ± 7 - 10 ± 5 - 9 ± 7 -
Calcitriol 32 ± 5 49ab ± 6 37 0 25a ± 11 10 5 ± 8 24 ± 2 14
PRI-2191 28 ± 4 46ab ± 5 34 0 14 ± 7 10 0 12 ± 4 9
PRI-2201 29 ± 5 48ab ± 6 35 0 14 ± 7 10 0 16 ± 7 9
PRI-2205 8 ± 3 24ab ± 8 16 9 ± 6 24 ± 6 18 13 ± 10 41ab ± 10 17
[%] – proliferation inhibition.
%H = 100-[(100-E for cytostatic) × (100-E for calcitriol analog) /100], where E was the percentage of proliferation inhibition.
On HT-29 and LoVo cells 5-FU was used in concentrations of 0.1 μg/ml and on MC38/0 – 0.01 μg/ml. Vitamin analogs were used in concentrations of 100 nM.
aP < 0.05 as compared to 5-FU; abP < 0.05 as compared to calcitriol or vitamin D analog.
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log, significantly enhanced the antitumor activity of
5-FU, but these results depend on the treatment regi-
men. We conclude that the most effective treatment
scheme and dose of both vitamin D analogs is when they
are injected s.c., three times a week and at a dose of
1 μg/kg/day for PRI-2191 and 10 μg/kg/day for PRI-
2205. Work-flow of in vivo studies on combined treat-
ment with vitamin D analogs and 5-FU is summarized
in Figure 9. A similar administration schedule was ap-
plied for vitamin D active form in the first phase of clin-
ical trials. Patients with advanced malignancy received
calcitriol s.c. every other day. It has been shown that the
intermittent schedule and s.c. injection allow theControl 5-FU 5-FU+PRI-2191 5-FU+
FL2-A
Figure 7 Cell cycle distribution and E-cadherin expression on HT-29 c
or its analogs alone and combined with 5-FU for 120 h in the case of the c
and its analogs were used in concentrations of 100 nM, 5-FU was used at a
expression analysis. * P < 0.05 as compared to control, ** P < 0.05 as compaapplication of calcitriol at doses up to 4–5 fold higher
(with tolerable toxicity) than is the case with oral appli-
cation. However, calcitriol alone did not show significant
antitumor activity [10].
Applying this optimal schedule of combined therapy,
we observed a significant decrease of tumor growth, and
also a prolongation of survival time of mice in compari-
son with 5-FU given alone. Most recently published epi-
demiological studies have shown that diagnosis in the
summer and autumn months has been associated with
better survival. Authors have suggested that exposure to
sunlight and the subsequent higher levels of skin vitamin
D synthesis at the time of diagnosis or treatment might
be the basis of the patients’ improved survival [28].PRI-2205
ells. Human colon cancer cells HT-29 were incubated with calcitriol
ell cycle assay and 48 h for E-cadherin expression analysis. Calcitriol
concentration of 0.1 μg/ml both for cell cycle and E-cadherin
red to 5-FU (Mann–Whitney U test).
Figure 8 Apoptosis of MC38/0 cells. Active caspase-3/7 (A) and subG1 stage (B) of MC38/0 murine colon cancer cells after 48 h incubation
with vitamin D analogs and/or 5-FU. Vitamin analogs were used in concentrations of 100 nM. 5-FU was used at concentrations of 50 μg/ml and
200 μg/ml. Asterisks indicate statistically significant results as compared to the control Tukey HSD test for active caspase-3/7 and the Mann–Whitney U test
for death cell (subG1) analysis.
Figure 9 Work-flow of in vivo studies on combined treatment with vitamin D analogs and 5-FU. ↑ synergistic; ↓ antagonism; ↔ additive
or no effect; o – observed; n/o – not observed; * - only in this experiment vitamin D analogs was administered after ended administration of
5-FU, in remaining experiments – simultaneously, as described in methods section.
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fully applied in the orthotopic model of colon cancer;
thus, in an environment similar to natural. Moreover,
the vitamin D analogs applied following the administra-
tion completion of 5-FU could prolong the antitumor
activity of this drug. However, better results were in gen-
eral observed for PRI-2191 than PRI-2205. Our in vitro
studies on HT-29 colon cancer cells showed that
PRI-2191 acts similarly to calcitriol or PRI-2201
(calcipotriol), whereas the mode of action of PRI-2205 dif-
fers. Also, our previous studies showed that PRI-2205
appeared to be less potent in the induction of cancer cell
differentiation in vitro as compared to calcitriol or
PRI-2191 [12,20]. Moreover, this is in accordance with the
results of ERK1/2 phosphorylation from our previous
in vivo studies on HT-29 tumors, where analog PRI-2191
used alone increased the level of p-ERK1/2, which is not
observed in tumors from mice treated with PRI-2205 [20].
Thymidylate synthase (TS) is an important target for
5-FU. Improved 5-FU activity might be achieved, e.g.,
by increasing and prolonging TS inhibition and preven-
tion of TS induction [29]. Our in vitro studies on HT-29
cells showed that PRI-2191 – the more active analog –
used along with 5-FU caused accumulation of cells in
the G0/G1 cell cycle phase with a parallel decreasing of
cells in the S stage. It is possible that this action of
PRI-2191 is responsible, in part, for an increased sensi-
tivity of colon cancer to 5-FU, because the expression of
TS is the highest during S phase progression and de-
creases when the cells do not proliferate [29]. A different
mechanism was observed in the case of analog PRI-2205
applied along with 5-FU. PRI-2205 combined with 5-FU
significantly increases cell percentage in the S cell cycle
phase compared to 5-FU applied alone, which indicates
that one of the direct mechanisms of combination ther-
apy may in part be attributable to the synergistic effect
of both compounds. Liu et al. reported that calcitriol
suppressed the expression of TS in colon cancer cells
and promoted a cytotoxic response to 5-FU [24]. Our
further studies on MC38/0 cells have shown that
PRI-2205 indicates a tendency to enhancing cell death
induction by 5-FU but in parallel decreases the activity
of caspase-3/7 compared to 5-FU, while 5-FU signifi-
cantly induces its activity. A similar effect was de-
scribed by Koren et al. after simultaneous incubation of
HT-29 cells with H2O2 and calcitriol. The increased
cytotoxic effect of combined treatment was shown, but
the activity of caspase-3 was decreased by calcitriol
compared to H2O2 [30].
The differentiation of colonic epithelial cells may be
regulated by extracellular Ca2+ and the CaSR. Moreover,
the induction of E-cadherin may be an important mech-
anism underlying the chemopreventive action of Ca2+
and calcitriol in colon cancer [31-33]. This is inaccordance with our studies, in which PRI-2191, similar
to calcitriol, promoted the expression of E-cadherin on
HT-29 cells in in vitro culture when used along with
5-FU. On the other hand, PRI-2205 lacked this activity.
We also observed that 5-FU combined with PRI-2191
causes a significant decrease in colon cancer metastasis
to lymph nodes compared to 5-FU applied alone. Pub-
lished data from clinical studies showed that E-cadherin
expression was significantly downregulated in gastro-
intestinal tumors with distant metastases [34]. Our ex-
periments showed that the antimetastatic potency of
PRI-2191 combined with 5-FU is correlated with an in-
crease in E-cadherin expression in vitro. On the other
hand, a different mechanism of antimetastatic activity
may also be considered. Our previous studies showed
that the in vivo inhibition of mouse Lewis lung (LLC)
tumor metastasis after treatment with calcitriol and ana-
log PRI-2191 was a consequence of diminished integrin
αvβ3 expression [35].
As we previously showed, both analogs used in in vivo
studies were less toxic than calcitriol. However,
PRI-2191 in therapeutic doses induces a rise in serum
calcium levels [19], which is not observed in the case of
PRI-2205 [12], these results are confirmed in the com-
bined treatment with 5-FU (Table 7). The slight increase
in serum calcium levels by analog PRI-2191 without any
evidence of toxicity may favorably affect cell-cell adhe-
sion mediated by E-cadherin which is dependent on ad-
equate calcium levels [31,32].
A number of in vitro and in vivo studies have shown
that calcitriol and its analogs enhance the antiproliferative
and antitumor efficacy of multiple chemotherapeutic
agents in different cancer models [17,36-39]. It has been
demonstrated that calcitriol combined with cisplatin
causes a higher tumor growth inhibition than cisplatin
alone in the treatment of mice bearing Y-79 human ret-
inoblastoma [40], as well as Lewis lung carcinoma tumors
[15]. However, in both studies combined therapy induced
significant toxicity. Neither combination used in our stud-
ies caused toxicity, expressed as a body weight decrease.
Thus, similar to oxaliplatin and irinotecan [20], which are
agents used as a components of FOLFOX (5-fluorouracil,
folinic acid and oxaliplatin) and FOLFOXIRI (5-fluoroura-
cil/leucovorin, oxaliplatin, and irinotecan) colon cancer
treatment protocols in clinics [41], 5-FU could be safely
used in combined treatment with vitamin D analogs.
Conclusion
In conclusion, both vitamin D analogs PRI-2191 and
PRI-2205 enhance the antitumor and antimetastatic ac-
tivity of 5-FU and capecitabine in colon cancer in vivo.
The combined therapy, in the optimal treatment
schedule, induces a synergistic effect and does not
show toxicity. Moreover, both analogs prolong the
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administration. These effects are correlated with a pro-
differentiating potential of analog PRI-2191, whereas
analog PRI-2205 acts through a different mechanism,
which requires further investigation.
Our data suggest that these vitamin D analogs might
be potentially applied to clinical use in order to enhance
the anticancer effect of 5-FU and also prolong its activity
in patients suffering from colorectal cancer. However,
the attention should be paid on such conclusions, be-
cause, the relationship between vitamin D and cancer
is not easy to interchangeable interpretation. A lot of
studies have shown a relationship between vitamin D
and cancer, however the direct movement from preclin-
ical to clinical conditions is impossible [42]. The dosage
of vitamin D analogs appears to be one of the important
reasons of indirect translation of preclinical to clinical
results. In our studies, lower doses of PRI-2191 act an-
tagonistically with 5-FU (summarized in Figure 9).
In clinical studies, in general, single agent vitamin D has
not been directly associated with objective tumor re-
sponse in phase I–II clinical trials. It is probably the re-
sult of the fact, that very few clinical studies have been
conducted using doses attaining the maximum tolerated
dose. There are also questions, if there is known the
maximal tolerated dose for patients [43]. Second import-
ant clue, is the heterogeneity of patient tumors, which
frequently lead to misinterpretation of the results. The
animal studies are conducted on particular histological
type of tumor, and some clinical studies showed, that
consideration of the histological type of tumors during
interpretation of the results may change the conclusions
[44]. As it is concluded in many papers analyzing
the preclinical and clinical studies on vitamin D com-
pounds, the further studies should be pointed to preclinical
analysis of the possible large panel of vitamin D targets and
the clinical studies should be better planned to eliminate
the known defects of those conducted [42,43].
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